Trial Profile

A clinical trial of SFA002 in mild to moderate Plaque Psoriasis

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SFA 002 (Primary)
Indications Plaque psoriasis
Focus Adverse reactions
Sponsors SFA Therapeutics

Most Recent Events

07 Mar 2025 Results presented in the SFA Therapeutics media release.
30 May 2024 Status changed from recruiting to active, no longer recruiting, according to a SFA Therapeutics media release.
30 May 2024 Positive topline efficacy and safety results from cohort 1 in 14 patients of its Phase 1b clinical trial of SFA-002, according to SFA Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com